| Project/Area Number |
16K20289
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Morita Shinkichi 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (10773955)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 咽頭癌 / 下咽頭癌 / 下咽頭がん / 早期診断 / うがい液 |
|---|
| Outline of Final Research Achievements |
In this study, to develop a new diagnosis method for early pharyngeal cancer and a new therapy, we tried to find a new diagnostic marker. We screened a high tumorigenic population of PDX-derived hypopharyngeal cancer in tumorigenic activity assay using immunodeficient NOG mice. We found that CD271high population possessed significantly high tumorigenic activity than CD271low population. To identify CD271 as a therapeutic target, we developed 5 clones of anti-CD271 antibodies. Among several clones, we chose one clone to humanize since this clone possessed highest affinity against CD271. We injected the humanized antibody with effector cells into cancer cell-xenografted mice, and found that tumor volume was significantly suppressed in the antibody-injected mice than vehicle-injected mice.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は難治である下咽頭癌に対して、新たな表面マーカーおよび治療標的を同定することができた。これまで、咽頭癌には特異的な治療標的が乏しく、今回新たに発見された意義は大きい。また、ヒト化抗体を用いて腫瘍抑制効果があることが確認できたため、臨床応用の期待ができる。今後、CD271の機能解析を含め、引き続き研究を実施する。
|
